Preclinical development of AMG 139, a human antibody specifically targeting IL-23

British Journal of Pharmacology

Volumn 172, Issue 1, 2015, Pages 159-172

  Kock K ^a   Pan, W J ^a   Gow, J M ^a   Horner, M J ^b   Gibbs, J P ^a   Colbert, A ^a   Goletz, T J ^a   Newhall, K J ^a   Rees, W A ^a   Sun, Y ^a   Zhang, Y ^a   O'Neill, J C ^a   Umble Romero, A N ^a   Prokop, S P ^a   Krill, C D ^a   Som, L ^a   Buntich, S A ^b   Trimble, M W ^c   Tsuji, W H ^a   Towne, J E ^a  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

^c 206 Carnegie Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG139; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 23; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; BRAZIKUMAB;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL ACTIVITY; BODY WEIGHT; CONTROLLED STUDY; CROHN DISEASE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; IMMUNOPHENOTYPING; IN VITRO STUDY; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; ORGAN WEIGHT; OSSIFICATION; PHARMACODYNAMICS; SINGLE DRUG DOSE; T LYMPHOCYTE; VITAL SIGN; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; HUMAN; IMMUNOLOGY; METABOLISM; NATURAL KILLER CELL; TOXICITY TESTING;

ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-23; KILLER CELLS, NATURAL; MACACA FASCICULARIS; MALE; TOXICITY TESTS;

EID: 84919657163     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12904     Document Type: Article

References (68)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Overview. Br J Pharmacol 170: 1449-1458.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic receptors. Br J Pharmacol 170: 1676-1705.
3. Animal and Plant Health Inspection Service USA (2005). Animal Welfare Act and Animal Welfare Regulations. Agriculture USDA (ed.). Washington, DC: US Department of Agriculture.
4. Bettelli E, Korn T, Kuchroo VK, (2007). Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 19: 652-657.
5. Blumberg H, Dinh H, Dean C Jr, Trueblood ES, Bailey K, Shows D, et al. (2010). IL-1RL2 and its ligands contribute to the cytokine network in psoriasis. J Immunol 185: 4354-4362.
6. Bowman EP, Chackerian AA, Cua DJ, (2006). Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Curr Opin Infect Dis 19: 245-252.
7. Buonocore S, Ahern PP, Uhlig HH, Ivanov II, Littman DR, Maloy KJ, et al. (2010). Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464: 1371-1375.
8. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, et al. (2007). A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 80: 273-290.
9. Cox JH, Kljavin NM, Ota N, Leonard J, Roose-Girma M, Diehl L, et al. (2012). Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice. Mucosal Immunol 5: 99-109.
10. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. (2003). Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
11. Davies B, Morris T, (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093-1095.
12. Dirks NL, Meibohm B, (2010). Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49: 633-659.
13. Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, et al. (2011). Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 50: 131-142.
14. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. (2006). A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314: 1461-1463.
15. Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A, et al. (2012). Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet 90: 636-647.
16. FDA (1979). The nonclinical laboratory studies good laboratory practice regulations united states health and human services food and drug administration.
17. Fieschi C, Casanova JL, (2003). The role of interleukin-12 in human infectious diseases: only a faint signature. Eur J Immunol 33: 1461-1464.
18. van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, et al. (2009). Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182: 5836-5845.
19. Food and Drug Administration (2014). Ustekinumab Label. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125261s114lbl.pdf (accessed 1/6/2014).
20. Gagliardi MC, Starnino S, Teloni R, Mariotti S, Dal Conte I, Di Carlo A, et al. (2011). Circulating levels of interleukin-17A and interleukin-23 are increased in patients with gonococcal infection. FEMS Immunol Med Microbiol 61: 129-132.
21. Geremia A, Arancibia-Cárcamo CV, Fleming MP, Rust N, Singh B, Mortensen NJ, et al. (2011). IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 208: 1127-1133.
22. Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, et al. (2012). A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 132: 304-314.
23. Guo YY, Wang NZ, Zhao S, Hou LX, Xu YB, Zhang N, (2013). Increased interleukin-23 is associated with increased disease activity in patients with rheumatoid arthritis. Chin Med J 126: 850-854.
24. Hotzel I, Theil F-P, Bernstein LJ, Prabhu S, Deng R, Quintana L, et al. (2012). A strategy for risk mitigation of antibodies with fast clearance. MAbs 4: 753-760.
25. Hunter CA, (2005). New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 5: 521-531.
26. Kastelein RA, Hunter CA, Cua DJ, (2007). Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 25: 221-242.
27. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, NC3Rs Reporting Guidelines Working Group (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
28. Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, et al. (2012). Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 27: 1535-1545.
29. Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, et al. (2012). Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol 27: 1252-1261.
30. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, et al. (2006). IL-23 promotes tumour incidence and growth. Nature 442: 461-465.
31. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. (2005). IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201: 233-240.
32. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. (2004). Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199: 125-130.
33. Lee TS, Yen HC, Pan CC, Chau LY, (1999). The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 19: 734-742.
34. Li Y, Chu N, Hu A, Gran B, Rostami A, Zhang GX, (2007). Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain 130 (Pt 2): 490-501.
35. Lin Y, Huang Y, Lu Z, Luo C, Shi Y, Zeng Q, et al. (2012). Decreased plasma IL-35 levels are related to the left ventricular ejection fraction in coronary artery diseases. PLoS ONE 7: e52490.
36. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
37. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. (2004). Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351: 2069-2079.
38. Meeran SM, Mantena SK, Meleth S, Elmets CA, Katiyar SK, (2006). Interleukin-12-deficient mice are at greater risk of UV radiation-induced skin tumors and malignant transformation of papillomas to carcinomas. Mol Cancer Ther 5: 825-832.
39. MHLW (1997). The Japanese good laboratory practice standards for safety studies on drugs pharmaceutical affairs bureau the ministry of health labour and welfare.
40. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, et al. (2003). Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198: 1951-1957.
41. National Research Council (U.S.). Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research (U.S.), National Academies Press (U.S.) (2011). Guide for the Care and Use of Laboratory Animals, 8th edn. National Academies Press: Washington, DC.
42. Nogueira E, Hamour S, Sawant D, Henderson S, Mansfield N, Chavele KM, et al. (2010). Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 25: 2209-2217.
43. OECD (1997). Principles on good laboratory practice: the organisation for economic cooperation and development.
44. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. (2000). Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715-725.
45. Pan WJ, Hsu H, Rees WA, Lear SP, Lee F, Foltz IN, et al. (2013a). Pharmacology of AMG 181, a human anti-alpha4 beta7 antibody that specifically alters trafficking of gut-homing T cells. Br J Pharmacol 169: 51-68.
46. Pan WJ, Rees WA, Towne JE, Gibbs JP, Colbert A, Goletz TJ, et al. (2013b). Clinical pharmacology, safety, and effects of anti-IL-23 antibody AMG 139. In: UEG Week. Available at: https://www.ueg.eu/education/document-detail/?name=clinical-pharmacology-safety-and-effects-of-anti-il-23-antibody-amg-139&file=103131 (accessed 15/6/2014).
47. Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. (2013a). Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 168: 844-854.
48. Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, et al. (2013b). Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. J Eur Acad Dermatol Venereol 28: 790-798.
49. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
50. Rathanaswami P, Babcook J, Gallo M, (2008). High-affinity binding measurements of antibodies to cell-surface-expressed antigens. Anal Biochem 373: 52-60.
51. Reddy M, Torres G, McCormick T, Marano C, Cooper K, Yeilding N, et al. (2010). Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J Dermatol 37: 413-425.
52. Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M, et al. (2011). A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 365: 1586-1596.
53. Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y, et al. (2012). An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol 11: 300-312.
54. Reichert JM, (2013). Antibodies to watch in 2013: mid-year update. mAbs 5: 513-517.
55. Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, et al. (2011). Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 306: 864-871.
56. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. (2012). Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 367: 1519-1528.
57. Schmidt C, Giese T, Ludwig B, Mueller-Molaian I, Marth T, Zeuzem S, et al. (2005). Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 11: 16-23.
58. Schulz SM, Köhler G, Schutze N, Knauer J, Straubinger RK, Chackerian AA, et al. (2008). Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17. J Immunol 181: 7891-7901.
59. Song GG, Bae SC, Choi SJ, Ji JD, Lee YH, (2012). Associations between interleukin-23 receptor polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis. Mol Biol Rep 39: 10655-10663.
60. Teng MW, Andrews DM, McLaughlin N, von Scheidt B, Ngiow SF, Möller A, et al. (2010). IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc Natl Acad Sci U S A 107: 8328-8333.
61. Teng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, et al. (2012). Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res 72: 3987-3996.
62. Traczewski P, Rudnicka L, (2012). Briakinumab for the treatment of plaque psoriasis. Biodrugs 26: 9-20.
63. Tzellos T, Kyrgidis A, Trigoni A, Zouboulis CC, (2012). Association of ustekinumab and briakinumab with major adverse cardiovascular events: an appraisal of meta-analyses and industry sponsored pooled analyses to date. Dermatoendocrinol 4: 320-323.
64. Tzellos T, Kyrgidis A, Zouboulis CC, (2013). Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 27: 622-627.
65. Vaknin-Dembinsky A, Balashov K, Weiner HL, (2006). IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 176: 7768-7774.
66. Wagner CL, Schantz A, Barnathan E, Olson A, Mascelli MA, Ford J, et al. (2003). Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 112: 37-53.
67. Yuzhalin AE, Kutikhin AG, (2012). Interleukin-12: clinical usage and molecular markers of cancer susceptibility. Growth Factors 30: 176-191.
68. Zhu KJ, Zhu CY, Shi G, Fan YM, (2012). Association of IL23R polymorphisms with psoriasis and psoriatic arthritis: a meta-analysis. Inflamm Res 61: 1149-1154.